Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Rights Issue
    • Top 40 Shareholders
    • Top 40 Option Holders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

Ethics Approval for New HCV Three Month Dosing Study

21 November 2013 by Justine Bednorz

Ethics Approval for New HCV Three Month Dosing Study

Categories 2013, ASX Announcements
Presentation to Annual General Meeting
Independent Research Validates Biotron HCV Drug Candidate
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 24 April 2025        Legal Notices and Privacy
Cleantalk Pixel